Abstract Details

Title Machine Learning Evaluation of Multiple Sclerosis Patients During the Time of COVID-19

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 018

Objective

To establish correlation of a clinical EDSS with BeCare’s app derived EDSS.

Background

The COVID-19 pandemic has highlighted the need for remote assessments of neurologic function in MS patients. Quantitative assessments of neurologic function, such as the Expanded Disability Status Scale (EDSS) routinely inform clinical decision-making in MS clinics. The BeCare app was developed to serve not only as a digital equivalent for the EDSS, but also as a tool to monitor disability progression remotely.

Design/Methods

Subjects were categorized by EDSS of Control (0), Mild (1.0- 3.0), Moderate (3.5 – 6.0) or Severe [6.5 – 9.0]. EDSS was established at baseline and at 3 month followup. Clinical scoring was compared to machine learning algorithm (MLA) obtained using Mobile App-derived data collected during the office visit. Of the 25 enrolled patients, 17 patients completed all app functions at baseline and 14 at followup.

Results The Chi-Squared test, used for the statistical analysis, assumes that observed frequencies (MLA) for a categorical variable match the expected frequencies (clinical). For a Chi-square test, a P-value that is greater than the significance level indicates there is sufficient evidence to conclude that the observed distribution is the same as the expected distribution based on the clinical EDSS scores. At the first study collection using a confidence interval of 95% resulted in a Xi-Squared value of 6.251 which is less than the critical value of 7.815 with a P-value of 0.08. At the second study collection, using a confidence interval of 95% resulted in a Xi-Squared value of 1.905 which is less than the critical value of 7.815 along with a P-value of 0.592

Conclusions

The BeCare App closely replicates clinical assessment of disease severity (categorized as mild, moderate, or severe). Remote monitoring for disease progression will serve to advance treatment of MS patients during and after the Pandemic.

Authors/Disclosures
Sharon Stoll, DO (Stoll Medical Group) PRESENTER	Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for roche Genentech. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi/genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Stoll has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for alexion. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Stoll has stock in BeCare Link LLC. Dr. Stoll has stock in Global Consult MS .
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Timothy K. Vartanian, MD, PhD (Weill Cornell Medical College)	Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Vartanian has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Vartanian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tisch MS Center. Dr. Vartanian has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Charisse D. Litchman, MD	Dr. Litchman has received personal compensation for serving as an employee of BeCare . Dr. Litchman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nurx. Dr. Litchman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan.

��ɫ��

��ɫ��